Lansoprazole

Lansoprazole
Systematic (IUPAC) name
(RS)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
Clinical data
Trade names Prevacid
AHFS/Drugs.com monograph
MedlinePlus a695020
Licence data US FDA:link
Pregnancy cat. B3(AU) B(US)
Legal status OTC (US) Rx Only
Routes Oral, IV
Pharmacokinetic data
Bioavailability 80% or more
Protein binding 97%
Metabolism Hepatic (CYP3A4- and CYP2C19-mediated)
Half-life 1–1.5 hours
Excretion Renal and fecal
Identifiers
CAS number 103577-45-3 Y
ATC code A02BC03
PubChem CID 3883
DrugBank APRD00077
ChemSpider 3746 Y
UNII 0K5C5T2QPG Y
KEGG D00355 Y
ChEBI CHEBI:6375 Y
ChEMBL CHEMBL480 Y
Chemical data
Formula C16H14F3N3O2S 
Mol. mass 369.363 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Lansoprazole ( /lænˈsprəzl/ lan-soh-prə-zohl; INN) is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol, Monolitum). It was first approved by the U.S. Food and Drug Administration (FDA) in 1995.[1]

Prevacid patent protection expired on November 10, 2009.[2][3] As a result, prescription Lansoprazole is now available in the form of a generic drug. As of November 12, 2009 (2009 -11-12), Lansoprazole is available over-the-counter (OTC) in the U.S. in a 15 mg dose marketed by Novartis as Prevacid 24HR.[4][5][6]

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.[7] Lansoprazole is a racemate [1:1-mixture of the enantiomers dexlansoprazole (Kapidex) and levolansoprazole].[8] Dexlanprantazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,[9] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.[10] Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.[11]

Contents

Indications

Lansoprazole is indicated for:

Drug interactions

Using Prevacid for Treating H. Pylori Infections Treatment to kill Helicobacter pylori (H. pylori) involves using two other drugs besides Prevacid. This treatment is known as "triple therapy." Triple therapy to kill H. pylori involves taking Prevacid 30 mg twice a day, plus amoxicillin 1,000 mg (twice daily) and clarithromycin 500 mg (twice daily). All three medications are taken for 10 or 14 days.

Side effects

Proton-pump inhibitors may be associated with a greater risk of hip fractures,[15] Clostridium difficile-associated diarrhea.[16] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.[17]

Brand names

The drug is sold under several brand names, including:[1]

Lansoprazole is also available as a generic drug in the US, UK, Canada, Belgium, Finland,[18] France, Colombia, Italy, Sweden,[19] and Mexico.

References

  1. ^ a b Mosby's Drug Consult: Lansoprazole
  2. ^ Prevacid drug patents
  3. ^ Teva to release Prevacid version when patent expires
  4. ^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (PDF) (Press release). November 12, 2009. http://www.prevacid24hr.com/pdfs/News%20media%20release%20-%20Prevacid24HR%20Launch%20-%20November%202009.pdf. Retrieved 2009-11-13. 
  5. ^ "Prevacid 24HR Patient Package Insert" (PDF). November 12, 2009. http://www.prevacid24hr.com/pdfs/PackageInsert.pdf. Retrieved 2009-11-13. 
  6. ^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (Press release). November 12, 2009. http://www.novartis.com/newsroom/media-releases/en/2009/1354451.shtml. Retrieved 2009-11-13. 
  7. ^ http://www.patient.co.uk/showdoc/30002943/
  8. ^ http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf
  9. ^ a b "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. http://www.rxlist.com/cgi/generic/lansop_cp.htm. Retrieved 2007-04-14. 
  10. ^ "Prevacid 24HR Fact Sheet" (PDF). November 12, 2009. http://www.prevacid24hr.com/pdfs/Prevacid24HR_Product_Fact_Sheet.pdf. Retrieved 2009-11-13. 
  11. ^ Effects on 24-Hour Intragastric pHFreston M.D., Ph.D., James; Yi-Lin Chiu, Ph.D., Wei-Jian Pan, Ph.D., Nancy Lukasik, B.S.N., and Jörg Täubel, M.D., A.F.P.M. (2001). "Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously". American Journal of Gastroenterology 96 (7): 2058–2065. doi:10.1111/j.1572-0241.2001.03939.x. ISSN 0002-9270. OCLC 440925790. PMID 11467632. 
  12. ^ Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [1]
  13. ^ K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225
  14. ^ Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL. Dermatology. St. Louis: Mosby. p. 154. ISBN 1-4160-2999-0. .
  15. ^ Yang YX, Lewis JD, Epstein S, Metz DC (December 2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA 296 (24): 2947–53. doi:10.1001/jama.296.24.2947. PMID 17190895. 
  16. ^ "Proton pump inhibitors and Clostridium difficile". Bandolier. 2003. http://www.medicine.ox.ac.uk/bandolier/booth/Pharmacy/PPIcdiff.html. Retrieved 2007-07-13. 
  17. ^ Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (May 2009). "Acid-suppressive medication use and the risk for hospital-acquired pneumonia". JAMA 301 (20): 2120–8. doi:10.1001/jama.2009.722. PMID 19470989. 
  18. ^ "Vastaavat tuotteet - hintavertailu" (in Finnish). http://www.terveyskirjasto.fi/terveysportti/geneerinen.substituutio?p_ryhma=0000130030. 
  19. ^ "FASS.se, accessed 2010-02-13" (in Swedish). http://www.fass.se/LIF/produktfakta/substance_products.jsp?substanceId=IDE4POFNUB4MJVERT1. 

External links